Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN1286
- Development stage
- Discontinued
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GEN1286 is a bispecific antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors. It targets both the epidermal growth factor receptor (EGFR) and c-Met (hepatocyte growth factor receptor), functioning as an inhibitor of these pathways. The drug is designed to deliver cytotoxic payloads directly to tumor cells expressing these receptors, thereby inhibiting tumor growth and survival. GEN1286 is administered intravenously and is currently in Phase 1/2 clinical trials for patients with advanced malignant solid neoplasms. The original developer was ProfoundBio; following its acquisition by Genmab, development has continued under Genmab[3][4][5][7].
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on GEN1286.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN1286.